Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Limited has announced the issuance of 1,800,968 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX) as of December 5, 2025. This move is part of the company’s strategy to enhance its financial position and support its ongoing research and development efforts in the biotechnology sector, potentially impacting its market presence and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited operates in the biotechnology industry, focusing on the development of immunotherapy treatments for cancer and autoimmune diseases. The company is known for its innovative approach to leveraging the body’s immune system to fight diseases, with a particular emphasis on LAG-3 related technologies.
Average Trading Volume: 2,298,114
Technical Sentiment Signal: Sell
Current Market Cap: A$412.1M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.